CMS Just Moved $13 Billion in Medicare Advantage Payments. Here's What Healthcare Investors Need to Know.

Key Takeaways

• CMS froze risk‑adjustment model, adding $13 B to MA payments.
• Unlinked chart‑review exclusions cut plan revenue ~1.2%, shifting vendor demand.
• Star Ratings overhaul removes 11 measures, reshapes health‑equity vendor market.
• County‑level rate changes vary from –4.5% to +19.8%, affecting local plans.
• Investors must stress‑test portfolios for a possible CY 2028 recalibration.

Pulse Analysis

The Centers for Medicare & Medicaid Services (CMS) delivered a surprise 2.48% rate hike for Medicare Advantage (MA) in its CY 2027 announcement, translating into more than $13 billion of additional federal spending. The headline increase masks a deeper regulatory maneuver: CMS froze the risk‑adjustment model that determines per‑member payments, abandoning a planned -3.32% recalibration that would have nullified most of the growth. By keeping the existing model in place for a year, CMS gave insurers a short‑term cash‑flow reprieve while signaling that another adjustment could arrive as early as January 2027.

The freeze reshapes the vendor landscape in two critical ways. First, CMS excluded unlinked chart‑review records—diagnoses not tied to a specific encounter—from risk‑score calculations, cutting average plan revenue by about 1.2% and prompting a scramble for encounter‑based coding solutions. Second, the agency overhauled the Star Ratings program, stripping out 11 low‑variation measures and eliminating four health‑equity mandates, which removes a regulatory sales driver for many SDOH and equity analytics platforms. Companies that can pivot to prospective, encounter‑linked documentation or demonstrate ROI without a mandated equity mandate stand to capture new procurement dollars.

For investors, the regulatory window is both an opportunity and a warning sign. Geographic rate variation—from -4.5% to +19.8% at the county level—means that national headlines can mislead when assessing plan‑specific exposure. Valuations that assume the 2.48% increase as a permanent baseline risk mispricing, especially if a CY 2028 recalibration reintroduces a -3% adjustment. Diligence should focus on a portfolio company’s dependence on unlinked chart‑review revenue, its ability to support prospective risk capture, and its exposure to counties facing rate cuts. Leveraging the 12‑ to 18‑month stability period to stress‑test scenarios and reposition contracts can differentiate keepers from exit candidates.